Correspondence 0000950170-24-116975 from Athira Pharma, Inc. (ATHA) (CIK 0001620463) (LONA)
Athira Pharma, Inc. (ATHA) (CIK 0001620463)
Date: Oct. 24, 2024 · CIK: 0001620463 · Accession: 0000950170-24-116975
AI Filing Summary & Sentiment
File numbers found in text: 333-282738
Letter
October 24, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: Alan Campbell
Re:
Athira Pharma, Inc.
Registration Statement on Form S-3
Filed October 21, 2024
(File No. 333-282738)
Acceleration Request
Requested Date: October 28, 2024
Requested Time: 4:00 P.M. Eastern Daylight Time,
or as soon thereafter as practicable
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Athira Pharma, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-282738) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Michael Nordtvedt at (206) 883-2524 or Bryan King at (206) 883-2535.
[Signature page follows]
Securities and Exchange Commission
October 24, 2024
Page 2
Sincerely,
ATHIRA PHARMA, INC.
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
October 24, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: Alan Campbell
Re:
Athira Pharma, Inc.
Registration Statement on Form S-3
Filed October 21, 2024
(File No. 333-282738)
Acceleration Request
Requested Date: October 28, 2024
Requested Time: 4:00 P.M. Eastern Daylight Time,
or as soon thereafter as practicable
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Athira Pharma, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-282738) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Michael Nordtvedt at (206) 883-2524 or Bryan King at (206) 883-2535.
[Signature page follows]
Securities and Exchange Commission
October 24, 2024
Page 2
Sincerely,
ATHIRA PHARMA, INC.
/s/ Robert Renninger
Robert Renninger
Vice President of Finance
Enclosures
cc: Mark Litton, Athira Pharma, Inc.
Mark Worthington, Athira Pharma, Inc.
Michael Nordtvedt, Wilson Sonsini Goodrich & Rosati P.C.
Bryan D. King, Wilson Sonsini Goodrich & Rosati P.C.